Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Temporary decrease in human rabies vaccine supplies

Filetype[PDF-23.29 KB]


  • English
    • Details You May Also Like

    Details:

    • Journal Article:
      HAN
    • Corporate Authors:
      Centers for Disease Control and Prevention (U.S.)
    • Description:
      Friday, June 20, 2008, 14:30 EDT (2:30 PM EDT)

      CDCHAN-00276-2008-06-20-ADV-N

      The Centers for Disease Control and Prevention (CDC) has been notified that Novartis Vaccines, maker of Rab Avert (Rabies Vaccine), will temporarily cease to provide their rabies vaccine for both pre- and post-exposure prophylaxis uses to health care providers. This includes physicians, nurse practitioners, hospitals, clinics, etc. A second company, Sanofi Pasteur, produces IMOVAX Rabies (Rabies Vaccine), and will continue to supply vaccine to health care providers for post-exposure prophylaxis (PEP). In certain circumstances, such as an allergic reaction to one company's vaccine product, the other company's vaccine product can be obtained to complete a vaccination series after consultation with state health departments and CDC, on a case-by-case basis. Overall, both manufacturers have limited supplies of rabies vaccine, necessitating the need for judicious use of these products by health care providers. (It is expected that additional Rab Avert will be available on the market in July 2008. When that occurs, it is expected that the demand for pre-exposure vaccinations can be fully met with Rab Avert.)

      Due to temporarily limited supplies, distribution of vaccine for pre-exposure prophylaxis (PreP) will be approved by state and federal public health authorities. Priority will be given for those individuals at greatest rabies exposure risk (e.g., rabies laboratory workers, animal control officers, veterinary staff, wildlife workers) and in consideration of available rabies vaccine supplies. In lower risk rabies exposure categories (e.g., travelers, veterinary students, etc.), human rabies PreP should be delayed until vaccine supply levels are restored.

    • Subjects:
    • Series:
      HAN ; 276
    • Document Type:
      HAN Health Advisory
    • Place as Subject:
      United States
    • Location:
      North America
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov